On June 22, 2021, Pear Therapeutics, the leader in developing and commercializing prescription digital therapeutics to treat serious disease, and Thimble Point Acquisition Corp., a special purpose acquisition company whose management team is associated with the Pritzker Vlock Family Office, announced they have entered into a definitive business combination agreement. In addition, they announced a $125 million PIPE financing.

Upon closing of the business combination, the combined company will be named Pear Holdings Corp. and will be led by Pear’s current management team. The combined company’s common stock is expected to be listed on Nasdaq under the new ticker symbol “PEAR.” Net proceeds from the business combination and the PIPE investment will be used to further capitalize Pear’s category-leading position by investing in commercialization of Pear’s three FDA-authorized products, advancing Pear’s pipeline, and scaling its end-to-end platform.

The combination is expected to be completed in the second half of 2021.

Wilson Sonsini Goodrich & Rosati is representing Temasek, Pear Therapeutics' largest stockholder, in the transaction.

The Wilson Sonsini team advising Temasek includes Barry Taylor, Richard Blake, Yingting Zhang, Jonathan Zhu, Derek Wallace, Joe Mandry, Stephen Heifetz, Anne Seymour, Jonathan Davey, and Christopher Williams.

For more information, please see Pear Therapeutics' press release.